Cargando…
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
BACKGROUND: Vilobelimab, an anti-C5a monoclonal antibody, was shown to be safe in a phase 2 trial of invasively mechanically ventilated patients with COVID-19. Here, we aimed to determine whether vilobelimab in addition to standard of care improves survival outcomes in this patient population. METHO...
Autores principales: | Vlaar, Alexander P J, Witzenrath, Martin, van Paassen, Pieter, Heunks, Leo M A, Mourvillier, Bruno, de Bruin, Sanne, Lim, Endry H T, Brouwer, Matthijs C, Tuinman, Pieter R, Saraiva, José F K, Marx, Gernot, Lobo, Suzana M, Boldo, Rodrigo, Simon-Campos, Jesus A, Cornet, Alexander D, Grebenyuk, Anastasia, Engelbrecht, Johannes M, Mukansi, Murimisi, Jorens, Philippe G, Zerbib, Robert, Rückinger, Simon, Pilz, Korinna, Guo, Renfeng, van de Beek, Diederik, Riedemann, Niels C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451499/ https://www.ncbi.nlm.nih.gov/pubmed/36087611 http://dx.doi.org/10.1016/S2213-2600(22)00297-1 |
Ejemplares similares
-
Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients
por: Lim, Endry H. T., et al.
Publicado: (2023) -
The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19
por: Vlaar, Alexander P. J., et al.
Publicado: (2022) -
87. The safety and efficacy advantage of blocking C5a vs C5 in critically ill, COVID-19 patients: Results from PANAMO, a Phase 3 randomized controlled trial
por: Burnett, Bruce P, et al.
Publicado: (2023) -
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
por: Vlaar, Alexander P J, et al.
Publicado: (2020) -
Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial
por: Lim, Endry H. T., et al.
Publicado: (2022)